Skip to content
10-Q

Quarterly Report

Gene Biotherapeutics, Inc.

0001564590-17-014411

← back to feed
Filed
Jul 28, 2017 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2017 · Jul 28, 2017 14.37M sh
Capex Q1 2017 · Mar 31, 2017 $1.87K
Cash And Equivalents Q1 2017 · Mar 31, 2017 $176.37K
Cash And Equivalents Q1 2017 · Dec 31, 2016 $930.4K
Cash And Equivalents Q1 2017 · Mar 31, 2016 $119.28K
Cash And Equivalents Q1 2017 · Dec 31, 2015 $21.55K
Stockholders Equity Q1 2017 · Mar 31, 2017 −$3.72M
Stockholders Equity Q1 2017 · Dec 31, 2016 −$3.14M
Current Liabilities Q1 2017 · Mar 31, 2017 $4.31M
Current Liabilities Q1 2017 · Dec 31, 2016 $4.39M
Total Liabilities Q1 2017 · Mar 31, 2017 $4.32M
Total Liabilities Q1 2017 · Dec 31, 2016 $4.4M
Current Assets Q1 2017 · Mar 31, 2017 $215.57K
Current Assets Q1 2017 · Dec 31, 2016 $940.82K
Total Assets Q1 2017 · Mar 31, 2017 $373.93K
Total Assets Q1 2017 · Dec 31, 2016 $1.11M
Sga Expense Q1 2017 · Mar 31, 2017 $521.22K
Sga Expense Q1 2017 · Mar 31, 2016 $340.67K
Rd Expense Q1 2017 · Mar 31, 2017 $130.76K
Rd Expense Q1 2017 · Mar 31, 2016 $83.33K
Net Income Q1 2017 · Mar 31, 2017 −$580.12K
Net Income Q1 2017 · Mar 31, 2016 −$426.58K
Operating Income Q1 2017 · Mar 31, 2017 −$651.98K
Operating Income Q1 2017 · Mar 31, 2016 −$424K